The Acute Effect of Low-carb Diet on the Plasma Fatty Acid Composition in Type 2 Diabetes
- Conditions
- Type 2 Diabetes
- Interventions
- Dietary Supplement: Low carbohydrate
- Registration Number
- NCT05498688
- Lead Sponsor
- Odense University Hospital
- Brief Summary
The investigators wishes to investigate the acute effect of a low carbohydrate meal on the plasma fatty acid (FA) composition compared with a control meal in a cross-over study of patients with type 2 diabetes (T2D).
In two trial days 12 participants with T2D will either have a low carbohydrate meal or control meal, measurements will be performed at baseline and continuously over 5 hours.
- Detailed Description
Type 2 diabetes (T2D) is the most common metabolic disorder worldwide, and with an increasing prevalence T2D has become a major healthcare burden.
Low carbohydrate diet (LCD) has become increasingly popular as a method of improving glycemic control in patients with type 2 diabetes. However, the higher content of especially saturated fat in LCD has raised concerns about harmful effects.
A previous study has shown increase in non esterified fatty acids after a low carbohydrate meal, but it still needs to be investigated how a low carbohydrate meal affects the plasma FA composition.
The aim of this project is to investigate the hypothesis that a single low carbohydrate meal results in an improved plasma FA composition in patients with T2D and that this, at least in part, corresponds to the changes observed after 6 months LCD.
The study will be conducted as a cross-over trial with 12 participants with T2D. The participants will randomly be assigned to either start with the low carbohydrate meal or a control meal with a 2 weeks washout period.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 12
- Duration of established type 2 diabetes for more than six months and less than five years, but duration of type 2 diabetes for up to 10 years if the current treatment consists of ≤ 2 oral antidiabetic drugs without insulin.
- HbA1c in compliance with type 2 diabetes (above 48 mmol/mol), with or without use of glucose-lowering pharmacotherapy, but without need for adjustment of antidiabetic treatment.
- Stable antidiabetic treatment three months prior to inclusion.
- Well treated dyslipidemia (LDL cholesterol < 2.5 mmol/l and total cholesterol < 4.5 mmol/l at inclusion) with or without statins.
- BMI ≥ 25.
- Age ≥ 18 years.
- All participants have to understand oral and written Danish.
- All participants have to sign an informed consent after oral and written information on experimental design.
- Significant comorbidity, including liver disease.
- A history of cancer < 5 years or current chemotherapy.
- Other severe co-morbidity that could interfere with study compliance or safety (e.g. previous gastrointestinal operations, liver disease, history of eating disorder, current alcohol overuse or hypoglycemic unawareness).
- Current treatment with glucocorticoids (systemic).
- Continuous treatment with steatosis-inducing drugs.
- Treatment with antibiotics during the last two months before inclusion.
- Low-carbohydrate diet prior to inclusion, or other restrictive diet.
- Weight-loss > 10 kg over the last three months before inclusion.
- Pregnancy or expected pregnancy within the next 6 months.
- Elevated blood pressure (180/110) with or without antihypertensives.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Low carbohydrate Low carbohydrate The intervention meal is a low-carbohydrate meal composed of 15 E% carbohydrates, 20 E% protein and 65 E% fat
- Primary Outcome Measures
Name Time Method Plasma fatty acid composition 5 hours Quantified as weight percentage (wt%) of total plasma phospholipid FA
- Secondary Outcome Measures
Name Time Method Glucose-Dependent Insulinotropic Polypeptide (GIP) 5 hours Subjective appetite 5 hours Visual analog scale - mm. 0 mm - 100 mm. 0 mm = none and 100 mm = very strong
Plasma glucose 5 hours Serum insulin 5 hours Plasma free fatty acid 5 hours LDL cholesterol 5 hours Triglycerides 5 hours Glucagon Like Peptide 1 (GLP1) 5 hours HDL cholesterol 5 hours Peptide YY (PYY) 5 hours Plasma ketones 5 hours Total cholesterol 5 hours Other lipoprotein fractions 5 hours Cholecystokinin (CCK) 5 hours Ghrelin 5 hours
Trial Locations
- Locations (1)
Odense University Hospital
🇩🇰Odense, Denmark